The FDA has cleared LumosityRx to improve attention function in adults aged 22 to 55 years with primarily inattentive or combined-type ADHD.

The FDA has expanded the approval of Addyi to include the treatment of hypoactive sexual desire disorder in women less than 65 years.

Danielle Nicole Larson, MD, discusses the mental health burden on patients with tardive dyskinesia, and considerations for clinicians who manage this condition.

Experts highlight how nurse practitioners can use lifestyle medicine and nutrition to reduce chronic disease and improve outcomes.

Provisional data indicates a slight dip in US suicide rates in 2024, representing 13.7 deaths per 100,000 people. HealthDay News — The U.S. suicide rate dipped slightly in 2024, offering a small but ...